25 XP   0   0   10

Adverum Biotechnologies Inc
Buy, Hold or Sell?

Let's analyse Adverum together

PenkeI guess you are interested in Adverum Biotechnologies Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Adverum Biotechnologies Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Adverum Biotechnologies Inc

I send you an email if I find something interesting about Adverum Biotechnologies Inc.

Quick analysis of Adverum (30 sec.)










What can you expect buying and holding a share of Adverum? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.02
Expected worth in 1 year
$-0.70
How sure are you?
17.5%

+ What do you gain per year?

Total Gains per Share
$-4.72
Return On Investment
-41.0%

For what price can you sell your share?

Current Price per Share
$11.53
Expected price per share
$9.7 - $29.70
How sure are you?
50%

1. Valuation of Adverum (5 min.)




Live pricePrice per Share (EOD)

$11.53

Intrinsic Value Per Share

$-56.24 - $-29.49

Total Value Per Share

$-52.22 - $-25.47

2. Growth of Adverum (5 min.)




Is Adverum growing?

Current yearPrevious yearGrowGrow %
How rich?$83.4m$229.2m-$110.4m-93.0%

How much money is Adverum making?

Current yearPrevious yearGrowGrow %
Making money-$29.2m-$38.6m$9.3m31.9%
Net Profit Margin-201.8%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Adverum (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#411 / 1019

Most Revenue
#514 / 1019

Most Profit
#786 / 1019

Most Efficient
#639 / 1019

What can you expect buying and holding a share of Adverum? (5 min.)

Welcome investor! Adverum's management wants to use your money to grow the business. In return you get a share of Adverum.

What can you expect buying and holding a share of Adverum?

First you should know what it really means to hold a share of Adverum. And how you can make/lose money.

Speculation

The Price per Share of Adverum is $11.53. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Adverum.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Adverum, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.02. Based on the TTM, the Book Value Change Per Share is $-1.18 per quarter. Based on the YOY, the Book Value Change Per Share is $1.38 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Adverum.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.14-9.9%-1.41-12.2%-0.70-6.1%-0.61-5.3%-0.55-4.7%
Usd Book Value Change Per Share-0.93-8.0%-1.18-10.2%1.3812.0%0.040.4%0.100.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.93-8.0%-1.18-10.2%1.3812.0%0.040.4%0.100.9%
Usd Price Per Share0.75-1.14-1.01-5.59-8.06-
Price to Earnings Ratio-0.16--0.20--0.55--4.43--5.01-
Price-to-Total Gains Ratio-0.81--0.94--2.29--14.81--12.94-
Price to Book Ratio0.19-0.21-0.37-1.62-1.58-
Price-to-Total Gains Ratio-0.81--0.94--2.29--14.81--12.94-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share11.53
Number of shares86
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-1.180.04
Usd Total Gains Per Share-1.180.04
Gains per Quarter (86 shares)-101.573.59
Gains per Year (86 shares)-406.2814.36
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-406-4160144
20-813-82202918
30-1219-122804332
40-1625-163405746
50-2031-204007260
60-2438-244608674
70-2844-2852010188
80-3250-32580115102
90-3656-36640129116
100-4063-40700144130

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.044.01.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%7.033.00.017.5%9.034.02.020.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.045.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%7.033.00.017.5%9.034.02.020.0%

Fundamentals of Adverum

About Adverum Biotechnologies Inc

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Fundamental data was last updated by Penke on 2024-04-10 23:42:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Adverum Biotechnologies Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Adverum earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Adverum to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Adverum Biotechnologies Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-201.8%+201.8%
TTM-201.8%YOY--201.8%
TTM-201.8%5Y-1,015.2%+813.4%
5Y-1,015.2%10Y-3,353.5%+2,338.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--196.9%+196.9%
TTM-201.8%-211.2%+9.4%
YOY--279.3%+279.3%
5Y-1,015.2%-436.8%-578.4%
10Y-3,353.5%-599.3%-2,754.2%
1.1.2. Return on Assets

Shows how efficient Adverum is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Adverum to the Biotechnology industry mean.
  • -13.7% Return on Assets means that Adverum generated $-0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Adverum Biotechnologies Inc:

  • The MRQ is -13.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.7%TTM-13.5%-0.2%
TTM-13.5%YOY-10.9%-2.6%
TTM-13.5%5Y-9.3%-4.2%
5Y-9.3%10Y-8.3%-1.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.7%-13.6%-0.1%
TTM-13.5%-12.9%-0.6%
YOY-10.9%-11.9%+1.0%
5Y-9.3%-14.2%+4.9%
10Y-8.3%-16.2%+7.9%
1.1.3. Return on Equity

Shows how efficient Adverum is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Adverum to the Biotechnology industry mean.
  • -28.4% Return on Equity means Adverum generated $-0.28 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Adverum Biotechnologies Inc:

  • The MRQ is -28.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -25.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.4%TTM-25.7%-2.7%
TTM-25.7%YOY-17.2%-8.6%
TTM-25.7%5Y-14.1%-11.7%
5Y-14.1%10Y-10.9%-3.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.4%-17.0%-11.4%
TTM-25.7%-16.1%-9.6%
YOY-17.2%-15.4%-1.8%
5Y-14.1%-20.0%+5.9%
10Y-10.9%-21.1%+10.2%

1.2. Operating Efficiency of Adverum Biotechnologies Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Adverum is operating .

  • Measures how much profit Adverum makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Adverum to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Adverum Biotechnologies Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-210.0%+210.0%
TTM-210.0%YOY--210.0%
TTM-210.0%5Y-1,134.0%+924.0%
5Y-1,134.0%10Y-2,525.3%+1,391.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--282.4%+282.4%
TTM-210.0%-225.8%+15.8%
YOY--288.4%+288.4%
5Y-1,134.0%-475.2%-658.8%
10Y-2,525.3%-624.7%-1,900.6%
1.2.2. Operating Ratio

Measures how efficient Adverum is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM2.560-2.560
TTM2.560YOY-+2.560
TTM2.5605Y20.404-17.844
5Y20.40410Y55.985-35.581
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.994-2.994
TTM2.5603.247-0.687
YOY-3.766-3.766
5Y20.4045.675+14.729
10Y55.9857.857+48.128

1.3. Liquidity of Adverum Biotechnologies Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Adverum is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.13 means the company has $4.13 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 4.125. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.846. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.125TTM3.846+0.280
TTM3.846YOY8.363-4.517
TTM3.8465Y12.595-8.749
5Y12.59510Y20.210-7.615
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1253.930+0.195
TTM3.8464.251-0.405
YOY8.3635.436+2.927
5Y12.5956.045+6.550
10Y20.2106.383+13.827
1.3.2. Quick Ratio

Measures if Adverum is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Adverum to the Biotechnology industry mean.
  • A Quick Ratio of 4.74 means the company can pay off $4.74 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 4.738. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.684. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.738TTM4.684+0.055
TTM4.684YOY13.191-8.508
TTM4.6845Y20.723-16.039
5Y20.72310Y27.415-6.692
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.7383.629+1.109
TTM4.6844.065+0.619
YOY13.1915.390+7.801
5Y20.7235.993+14.730
10Y27.4156.277+21.138

1.4. Solvency of Adverum Biotechnologies Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Adverum assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Adverum to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.52 means that Adverum assets are financed with 51.8% credit (debt) and the remaining percentage (100% - 51.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 0.518. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.470. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.518TTM0.470+0.048
TTM0.470YOY0.360+0.110
TTM0.4705Y0.273+0.197
5Y0.27310Y0.171+0.102
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5180.332+0.186
TTM0.4700.333+0.137
YOY0.3600.268+0.092
5Y0.2730.366-0.093
10Y0.1710.390-0.219
1.4.2. Debt to Equity Ratio

Measures if Adverum is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Adverum to the Biotechnology industry mean.
  • A Debt to Equity ratio of 107.3% means that company has $1.07 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Adverum Biotechnologies Inc:

  • The MRQ is 1.073. The company is able to pay all its debts with equity. +1
  • The TTM is 0.894. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.073TTM0.894+0.179
TTM0.894YOY0.567+0.327
TTM0.8945Y0.428+0.466
5Y0.42810Y0.252+0.176
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0730.380+0.693
TTM0.8940.389+0.505
YOY0.5670.334+0.233
5Y0.4280.432-0.004
10Y0.2520.465-0.213

2. Market Valuation of Adverum Biotechnologies Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Adverum generates.

  • Above 15 is considered overpriced but always compare Adverum to the Biotechnology industry mean.
  • A PE ratio of -0.16 means the investor is paying $-0.16 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Adverum Biotechnologies Inc:

  • The EOD is -2.523. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.165. Based on the earnings, the company is expensive. -2
  • The TTM is -0.198. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.523MRQ-0.165-2.358
MRQ-0.165TTM-0.198+0.033
TTM-0.198YOY-0.553+0.355
TTM-0.1985Y-4.430+4.232
5Y-4.43010Y-5.011+0.580
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.523-2.426-0.097
MRQ-0.165-2.552+2.387
TTM-0.198-2.656+2.458
YOY-0.553-4.143+3.590
5Y-4.430-6.252+1.822
10Y-5.011-6.108+1.097
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Adverum Biotechnologies Inc:

  • The EOD is -2.770. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.181. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.255. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.770MRQ-0.181-2.589
MRQ-0.181TTM-0.255+0.074
TTM-0.255YOY-0.674+0.419
TTM-0.2555Y-5.140+4.885
5Y-5.14010Y-7.396+2.256
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.770-3.199+0.429
MRQ-0.181-3.259+3.078
TTM-0.255-3.552+3.297
YOY-0.674-5.617+4.943
5Y-5.140-8.326+3.186
10Y-7.396-8.689+1.293
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Adverum is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.19 means the investor is paying $0.19 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Adverum Biotechnologies Inc:

  • The EOD is 2.867. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.187. Based on the equity, the company is cheap. +2
  • The TTM is 0.209. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD2.867MRQ0.187+2.680
MRQ0.187TTM0.209-0.022
TTM0.209YOY0.366-0.157
TTM0.2095Y1.621-1.412
5Y1.62110Y1.576+0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.8671.947+0.920
MRQ0.1872.116-1.929
TTM0.2092.095-1.886
YOY0.3662.836-2.470
5Y1.6213.443-1.822
10Y1.5763.791-2.215
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Adverum Biotechnologies Inc.

3.1. Institutions holding Adverum Biotechnologies Inc

Institutions are holding 80.026% of the shares of Adverum Biotechnologies Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31COMMODORE CAPITAL LP4.81810.65781000000000
2023-12-31Goldman Sachs Group Inc4.38720.00069105578454955699.8581
2023-09-30VR Adviser, LLC3.16711.0386573300268705469.1427
2023-12-31FMR Inc2.95080.00046124272-567653-8.4827
2023-12-31Morgan Stanley - Brokerage Accounts2.48150.00035150396-1825842-26.1723
2023-12-31Versant Venture Management LLC2.44190.9812506823300
2023-12-31BML Capital Management LLC2.19432.5968455425263925216.3283
2023-12-31Bank of America Corp2.07180.00034300023-469163-9.8374
2023-12-31Vanguard Group Inc2.01830.0001418903400
2023-12-31AIGH Capital Management, LLC1.52870.944931728191848834139.6416
2023-12-31Sonic GP LLC0.96361.7295200000000
2023-12-31Renaissance Technologies Corp0.90470.0022187765254791141.2043
2023-12-31BlackRock Inc0.675101401180-108-0.0077
2023-12-31Geode Capital Management, LLC0.41640.000186420600
2023-12-31Newtyn Management LLC0.39660.1216823096-201904-19.698
2023-12-31Worth Venture Partners, LLC0.37790.3191784346452678136.4853
2023-12-31Two Sigma Advisers, LLC0.22270.0008462300-30400-6.1701
2023-12-31Two Sigma Investments LLC0.21510.0008446396-71639-13.829
2023-12-31Soleus Capital Management, L.P.0.20480.03554250004250000
2023-12-31Quinn Opportunity Partners LLC0.19190.031239829800
Total 32.62858.461267720381+7983576+11.8%

3.2. Funds holding Adverum Biotechnologies Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Franklin Biotechnology Discovery A2.80661.094858203714663715403.2067
2024-02-29Franklin Biotechnology Discv A(acc)USD2.14820.4784455100202120083.0437
2024-01-31Fidelity Select Biotechnology1.96010.09254064992-1806500-30.7673
2024-02-29Vanguard Total Stock Mkt Idx Inv1.34460.0004278855400
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.61870.00251283099578044.7176
2023-08-31Galileo - Biotech Innovation Fund S USD0.33423.849269303500
2024-02-29iShares Core S&P Total US Stock Mkt ETF0.25390.00252645600
2024-01-31Fidelity Extended Market Index0.22880.0014474446171733.7555
2023-09-30BlackRock Extended Mkt Composite0.11070.002422955800
2023-12-31BlackRock Extended Equity Market K0.09660.0011200270-403-0.2008
2024-01-31Fidelity Total Market Index0.0620.000212864400
2024-01-31Fidelity Series Total Market Index0.05880.000212201400
2024-02-29Fidelity Enhanced Small Cap ETF0.05670.046117523-2034-1.7013
2023-12-31Fidelity VIP Disciplined Small Cap Init0.05480.022811364400
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.03860.0018011400
2024-02-29Vanguard Balanced Index Inv0.03660.00037600000
2023-12-31Northern Trust Extended Eq Market Idx0.0360.0017463600
2023-12-31NT Ext Equity Mkt Idx Fd - L0.0360.0017463600
2024-02-29Vanguard Instl Ttl Stk Mkt Idx InstlPls0.03260.00046750800
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.03260.000267508-2594046-97.4636
Total 10.34715.597421458108+2356909+11.0%

3.3. Insider Transactions

Insiders are holding 0.909% of the shares of Adverum Biotechnologies Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-07James Paul ScopaBUY1000013.5
2023-09-15Setareh SeyedkazemiSELL62015.2

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Adverum Biotechnologies Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.927-1.181+27%1.381-167%0.042-2321%0.101-1020%
Book Value Per Share--4.0225.723-30%4.044-1%4.096-2%5.011-20%
Current Ratio--4.1253.846+7%8.363-51%12.595-67%20.210-80%
Debt To Asset Ratio--0.5180.470+10%0.360+44%0.273+90%0.171+203%
Debt To Equity Ratio--1.0730.894+20%0.567+89%0.428+151%0.252+325%
Dividend Per Share----0%-0%-0%-0%
Eps---1.143-1.411+24%-0.702-39%-0.614-46%-0.547-52%
Free Cash Flow Per Share---1.041-1.106+6%-0.480-54%-0.484-53%-0.364-65%
Free Cash Flow To Equity Per Share---1.029-1.114+8%-0.466-55%-0.245-76%0.132-877%
Gross Profit Margin--1.0431.011+3%1.000+4%1.002+4%1.001+4%
Intrinsic Value_10Y_max---29.493--------
Intrinsic Value_10Y_min---56.243--------
Intrinsic Value_1Y_max---1.676--------
Intrinsic Value_1Y_min---3.080--------
Intrinsic Value_3Y_max---6.011--------
Intrinsic Value_3Y_min---11.522--------
Intrinsic Value_5Y_max---11.522--------
Intrinsic Value_5Y_min---22.386--------
Market Cap239303997.000+93%15624288.72023661623.745-34%88622368.638-82%440149514.977-96%374639963.799-96%
Net Profit Margin----2.0180%-0%-10.1520%-33.5350%
Operating Margin----2.1000%-0%-11.3400%-25.2530%
Operating Ratio---2.560-100%-0%20.404-100%55.985-100%
Pb Ratio2.867+93%0.1870.209-10%0.366-49%1.621-88%1.576-88%
Pe Ratio-2.523-1432%-0.165-0.198+20%-0.553+236%-4.430+2590%-5.011+2942%
Price Per Share11.530+93%0.7531.140-34%1.010-25%5.589-87%8.062-91%
Price To Free Cash Flow Ratio-2.770-1432%-0.181-0.255+41%-0.674+273%-5.140+2742%-7.396+3989%
Price To Total Gains Ratio-12.435-1432%-0.812-0.943+16%-2.289+182%-14.815+1725%-12.939+1494%
Quick Ratio--4.7384.684+1%13.191-64%20.723-77%27.415-83%
Return On Assets---0.137-0.135-1%-0.109-20%-0.093-32%-0.083-40%
Return On Equity---0.284-0.257-9%-0.172-40%-0.141-51%-0.109-62%
Total Gains Per Share---0.927-1.181+27%1.381-167%0.042-2321%0.101-1020%
Usd Book Value--83469000.000118773750.000-30%229232250.000-64%251940000.000-67%227450975.000-63%
Usd Book Value Change Per Share---0.927-1.181+27%1.381-167%0.042-2321%0.101-1020%
Usd Book Value Per Share--4.0225.723-30%4.044-1%4.096-2%5.011-20%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.143-1.411+24%-0.702-39%-0.614-46%-0.547-52%
Usd Free Cash Flow---21596000.000-22946500.000+6%-29976750.000+39%-24709950.000+14%-17027700.000-21%
Usd Free Cash Flow Per Share---1.041-1.106+6%-0.480-54%-0.484-53%-0.364-65%
Usd Free Cash Flow To Equity Per Share---1.029-1.114+8%-0.466-55%-0.245-76%0.132-877%
Usd Market Cap239303997.000+93%15624288.72023661623.745-34%88622368.638-82%440149514.977-96%374639963.799-96%
Usd Price Per Share11.530+93%0.7531.140-34%1.010-25%5.589-87%8.062-91%
Usd Profit---23714000.000-29291250.000+24%-38634000.000+63%-29961700.000+26%-22865300.000-4%
Usd Revenue---900000.000-100%-0%183500.000-100%286925.000-100%
Usd Total Gains Per Share---0.927-1.181+27%1.381-167%0.042-2321%0.101-1020%
 EOD+5 -3MRQTTM+19 -13YOY+6 -245Y+7 -2510Y+5 -27

4.2. Fundamental Score

Let's check the fundamental score of Adverum Biotechnologies Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.523
Price to Book Ratio (EOD)Between0-12.867
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.738
Current Ratio (MRQ)Greater than14.125
Debt to Asset Ratio (MRQ)Less than10.518
Debt to Equity Ratio (MRQ)Less than11.073
Return on Equity (MRQ)Greater than0.15-0.284
Return on Assets (MRQ)Greater than0.05-0.137
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Adverum Biotechnologies Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.505
Ma 20Greater thanMa 5013.817
Ma 50Greater thanMa 10017.323
Ma 100Greater thanMa 20012.989
OpenGreater thanClose11.720
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Tax Provision  19-217421-417-1,150-1,133
Income Tax Expense  19-217421-417-1,150-1,133



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets173,010
Total Liabilities89,541
Total Stockholder Equity83,469
 As reported
Total Liabilities 89,541
Total Stockholder Equity+ 83,469
Total Assets = 173,010

Assets

Total Assets173,010
Total Current Assets102,773
Long-term Assets70,237
Total Current Assets
Cash And Cash Equivalents 75,000
Short-term Investments 21,526
Other Current Assets 6,247
Total Current Assets  (as reported)102,773
Total Current Assets  (calculated)102,773
+/-0
Long-term Assets
Property Plant Equipment 67,030
Long-term Assets Other 1,231
Long-term Assets  (as reported)70,237
Long-term Assets  (calculated)68,261
+/- 1,976

Liabilities & Shareholders' Equity

Total Current Liabilities24,914
Long-term Liabilities64,627
Total Stockholder Equity83,469
Total Current Liabilities
Short-term Debt 10,409
Accounts payable 1,921
Other Current Liabilities 12,483
Total Current Liabilities  (as reported)24,914
Total Current Liabilities  (calculated)24,813
+/- 101
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt64,627
Long-term Liabilities  (as reported)64,627
Long-term Liabilities  (calculated)64,627
+/- 0
Total Stockholder Equity
Common Stock10
Retained Earnings -919,777
Accumulated Other Comprehensive Income -473
Other Stockholders Equity 1,003,709
Total Stockholder Equity (as reported)83,469
Total Stockholder Equity (calculated)83,469
+/-0
Other
Capital Stock10
Cash and Short Term Investments 96,526
Common Stock Shares Outstanding 10,121
Current Deferred Revenue101
Liabilities and Stockholders Equity 173,010
Net Debt 36
Net Invested Capital 83,469
Net Working Capital 77,859
Property Plant and Equipment Gross 81,542
Short Long Term Debt Total 75,036



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
386
0
0
0
1,085
51,613
54,789
167,239
161,906
292,691
283,715
273,829
264,319
252,934
264,345
256,571
234,583
221,929
208,579
198,210
201,905
257,158
246,585
225,907
213,495
221,047
209,884
205,525
222,727
348,599
331,176
507,711
482,567
461,551
526,147
490,581
439,727
407,394
374,955
332,362
308,372
275,577
241,429
196,770
173,010
173,010196,770241,429275,577308,372332,362374,955407,394439,727490,581526,147461,551482,567507,711331,176348,599222,727205,525209,884221,047213,495225,907246,585257,158201,905198,210208,579221,929234,583256,571264,345252,934264,319273,829283,715292,691161,906167,23954,78951,6131,085000386
   > Total Current Assets 
0
0
0
0
822
51,266
52,904
166,333
160,278
291,132
280,632
270,361
260,992
249,229
243,570
235,896
225,274
212,640
199,641
189,523
193,741
249,198
237,922
222,174
208,754
193,137
180,561
167,602
175,870
300,448
282,681
459,700
434,438
409,855
386,272
347,827
317,145
280,117
246,031
213,243
190,595
168,873
147,143
124,596
102,773
102,773124,596147,143168,873190,595213,243246,031280,117317,145347,827386,272409,855434,438459,700282,681300,448175,870167,602180,561193,137208,754222,174237,922249,198193,741189,523199,641212,640225,274235,896243,570249,229260,992270,361280,632291,132160,278166,33352,90451,2668220000
       Cash And Cash Equivalents 
357
0
0
0
564
50,679
52,428
165,329
159,404
290,125
200,537
200,676
259,080
247,082
241,302
231,271
222,170
71,569
39,523
31,713
70,519
152,716
155,451
159,673
154,949
144,107
97,808
73,171
65,897
130,162
27,359
72,696
62,424
45,422
47,299
32,971
34,195
89,652
91,870
84,430
68,431
67,552
111,187
105,366
75,000
75,000105,366111,18767,55268,43184,43091,87089,65234,19532,97147,29945,42262,42472,69627,359130,16265,89773,17197,808144,107154,949159,673155,451152,71670,51931,71339,52371,569222,170231,271241,302247,082259,080200,676200,537290,125159,404165,32952,42850,679564000357
       Short-term Investments 
0
0
0
0
0
0
0
0
0
88,276
79,103
68,210
37,732
37,732
0
0
0
137,934
157,895
154,929
119,966
94,321
79,425
58,209
50,130
45,381
79,834
88,814
100,138
166,904
252,780
381,766
367,305
358,596
316,544
299,734
270,993
181,403
143,971
118,834
117,158
96,733
30,266
11,716
21,526
21,52611,71630,26696,733117,158118,834143,971181,403270,993299,734316,544358,596367,305381,766252,780166,904100,13888,81479,83445,38150,13058,20979,42594,321119,966154,929157,895137,93400037,73237,73268,21079,10388,276000000000
       Net Receivables 
0
0
0
0
8
233
8
8
449
0
0
0
449
1,117
1,029
1,785
886
886
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,196
7,358
5,709
2,457
4,145
155
0
1,351
1,308
0
0
001,3081,35101554,1452,4575,7097,35816,19600000000000000008868861,7851,0291,1174490004498823380000
   > Long-term Assets 
0
0
0
0
263
347
1,885
906
1,628
1,559
3,083
3,468
3,327
3,705
20,775
20,675
9,309
9,289
8,938
8,687
8,164
7,960
8,663
3,733
4,741
27,910
29,323
37,923
46,857
48,151
48,495
48,011
48,129
51,696
139,875
142,754
122,582
127,277
128,924
119,119
117,777
106,704
94,286
72,174
70,237
70,23772,17494,286106,704117,777119,119128,924127,277122,582142,754139,87551,69648,12948,01148,49548,15146,85737,92329,32327,9104,7413,7338,6637,9608,1648,6878,9389,2899,30920,67520,7753,7053,3273,4683,0831,5591,6289061,8853472630000
       Property Plant Equipment 
4
0
0
0
69
107
509
817
1,085
1,421
2,945
3,330
3,187
3,565
3,985
4,335
4,169
4,149
3,798
3,347
3,024
2,820
2,525
2,594
3,586
26,737
28,150
36,760
45,847
47,133
47,477
46,993
47,101
47,423
133,465
137,332
119,060
122,097
121,999
116,461
113,861
102,850
90,328
68,254
67,030
67,03068,25490,328102,850113,861116,461121,999122,097119,060137,332133,46547,42347,10146,99347,47747,13345,84736,76028,15026,7373,5862,5942,5252,8203,0243,3473,7984,1494,1694,3353,9853,5653,1873,3302,9451,4211,085817509107690004
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,650
16,200
5,000
5,000
5,000
5,000
5,000
5,000
5,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000005,0005,0005,0005,0005,0005,0005,00016,20016,65000000000000000
       Other Assets 
0
0
0
0
194
240
1,376
89
543
138
138
138
140
140
16,790
16,340
5,140
5,140
5,140
5,340
5,140
140
1,138
1,139
1,155
1,173
1,173
1,163
1,010
1,018
1,018
1,018
1,028
4,273
6,410
5,422
3,522
5,180
6,925
2,658
3,916
0
3,958
3,920
0
03,9203,95803,9162,6586,9255,1803,5225,4226,4104,2731,0281,0181,0181,0181,0101,1631,1731,1731,1551,1391,1381405,1405,3405,1405,1405,14016,34016,790140140138138138543891,3762401940000
> Total Liabilities 
1,383
0
0
0
1,303
1,699
11,751
11,504
12,423
13,011
13,089
11,499
11,727
11,368
16,691
20,341
18,983
20,548
16,399
17,218
17,877
11,115
13,138
10,354
12,328
32,904
32,144
41,311
47,770
44,646
48,613
42,999
48,220
46,731
147,005
144,581
123,542
124,442
130,833
124,025
126,854
117,820
110,274
94,056
89,541
89,54194,056110,274117,820126,854124,025130,833124,442123,542144,581147,00546,73148,22042,99948,61344,64647,77041,31132,14432,90412,32810,35413,13811,11517,87717,21816,39920,54818,98320,34116,69111,36811,72711,49913,08913,01112,42311,50411,7511,6991,3030001,383
   > Total Current Liabilities 
839
0
0
0
1,162
1,608
3,991
4,461
5,471
7,628
7,864
6,496
6,574
5,556
7,897
10,649
9,896
11,966
8,313
9,613
10,674
9,274
11,374
10,065
10,719
10,610
10,149
17,746
19,408
16,767
21,254
16,111
20,871
19,923
20,530
25,326
21,320
23,237
30,620
28,621
32,246
46,472
44,518
28,856
24,914
24,91428,85644,51846,47232,24628,62130,62023,23721,32025,32620,53019,92320,87116,11121,25416,76719,40817,74610,14910,61010,71910,06511,3749,27410,6749,6138,31311,9669,89610,6497,8975,5566,5746,4967,8647,6285,4714,4613,9911,6081,162000839
       Short-term Debt 
0
0
0
0
0
0
1,597
1,995
3,687
2,485
3,331
3,691
4,073
3,404
4,141
5,816
6,547
6,609
5,076
5,948
6,848
6,766
7,356
7,666
0
3,826
3,942
4,044
4,034
4,025
4,221
4,435
4,473
4,512
4,185
4,224
1,886
2,359
6,292
11,236
13,241
26,265
25,396
10,324
10,409
10,40910,32425,39626,26513,24111,2366,2922,3591,8864,2244,1854,5124,4734,4354,2214,0254,0344,0443,9423,82607,6667,3566,7666,8485,9485,0766,6096,5475,8164,1413,4044,0733,6913,3312,4853,6871,9951,597000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
74
74
74
74
157
0
0
0
0
3,826
0
0
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000100003,8260000157747474740000000000000000
       Accounts payable 
522
0
0
0
769
946
1,576
1,627
951
2,787
1,896
1,141
605
486
2,419
3,067
1,474
3,383
1,125
1,580
1,731
685
2,125
1,736
1,707
1,752
740
3,382
4,103
4,663
10,367
3,034
2,810
2,056
2,259
2,517
1,387
3,245
4,698
846
2,238
2,863
1,418
2,170
1,921
1,9212,1701,4182,8632,2388464,6983,2451,3872,5172,2592,0562,8103,03410,3674,6634,1033,3827401,7521,7071,7362,1256851,7311,5801,1253,3831,4743,0672,4194866051,1411,8962,7879511,6271,576946769000522
       Other Current Liabilities 
317
0
0
0
393
662
5
26
20
43
324
101
1,013
607
109
75
25
124
262
235
245
577
1,140
593
9,012
370
450
1,412
2,636
2,491
565
543
1,325
919
2,742
2,326
2,017
17,633
19,630
16,539
16,767
17,344
1,998
1,663
12,483
12,4831,6631,99817,34416,76716,53919,63017,6332,0172,3262,7429191,3255435652,4912,6361,4124503709,0125931,14057724523526212425751096071,0131013244320265662393000317
   > Long-term Liabilities 
0
0
0
0
141
91
7,760
7,043
6,952
5,383
5,225
5,003
5,153
5,812
8,794
9,692
9,087
8,582
8,086
7,605
7,203
1,841
1,764
289
1,609
22,294
21,995
23,565
28,362
27,879
27,359
26,888
27,349
26,808
126,475
119,255
102,222
101,205
100,213
95,404
94,608
71,348
65,756
65,200
64,627
64,62765,20065,75671,34894,60895,404100,213101,205102,222119,255126,47526,80827,34926,88827,35927,87928,36223,56521,99522,2941,6092891,7641,8417,2037,6058,0868,5829,0879,6928,7945,8125,1535,0035,2255,3836,9527,0437,760911410000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
-1,597
-1,995
-3,687
-2,485
-3,331
-3,691
-4,073
-3,404
-4,141
-5,816
-6,547
-6,609
-5,076
-5,948
-6,848
-6,766
-7,356
-7,666
0
22,078
21,804
23,380
28,214
27,753
27,258
26,752
26,235
25,694
125,361
118,141
101,108
100,178
99,193
94,464
93,561
71,348
65,756
65,200
64,627
64,62765,20065,75671,34893,56194,46499,193100,178101,108118,141125,36125,69426,23526,75227,25827,75328,21423,38021,80422,0780-7,666-7,356-6,766-6,848-5,948-5,076-6,609-6,547-5,816-4,141-3,404-4,073-3,691-3,331-2,485-3,687-1,995-1,597000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
373
455
386
370
369
387
481
404
368
187
243
22,294
21,995
23,565
28,362
27,879
27,359
26,888
27,349
1,114
1,114
119,255
102,222
101,205
100,213
95,404
1,047
71,348
65,756
0
0
0065,75671,3481,04795,404100,213101,205102,222119,2551,1141,11427,34926,88827,35927,87928,36223,56521,99522,29424318736840448138736937038645537300000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
147
7,043
6,952
5,383
5,225
5,003
5,153
5,812
8,421
9,237
8,701
8,212
7,717
7,218
6,722
1,437
1,396
102
1,366
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,3661021,3961,4376,7227,2187,7178,2128,7019,2378,4215,8125,1535,0035,2255,3836,9527,043147000000
> Total Stockholder Equity
0
0
0
0
-218
49,914
43,038
155,735
149,483
279,680
270,626
262,330
252,592
241,566
247,654
236,230
215,600
201,381
192,180
180,992
184,028
246,043
233,447
215,553
201,167
188,143
177,740
164,214
174,957
303,953
282,563
464,712
434,347
414,820
379,142
346,000
316,185
282,952
244,122
208,337
181,518
157,757
131,155
102,714
83,469
83,469102,714131,155157,757181,518208,337244,122282,952316,185346,000379,142414,820434,347464,712282,563303,953174,957164,214177,740188,143201,167215,553233,447246,043184,028180,992192,180201,381215,600236,230247,654241,566252,592262,330270,626279,680149,483155,73543,03849,914-2180000
   Common Stock
0
0
0
0
0
1
-1,564
2
2
3
3
3
3
3
4
4
4
4
5
5
5
7
6
6
6
6
6
7
7
8
8
10
10
10
10
10
10
10
10
10
10
10
10
10
10
1010101010101010101010101010887766666755544443333322-1,564100000
   Retained Earnings Total Equity00-863,178-831,6680-769,876-729,745-685,984-648,076-613,667-575,305-530,972-502,536-464,904-437,135-407,935-385,029-366,104-349,986-335,032-320,543-304,884-283,926-265,116-254,062-239,273-225,444-214,014-197,915-175,521-161,220-99,560-84,168-70,074-55,991-46,224-36,715-26,324-18,069000000
   Accumulated Other Comprehensive Income 
0
0
0
0
27
27
26
11
10
-33
12
-3
-11
9
4
-19
-7
-212
-403
-551
-963
-1,021
-908
-854
-799
-754
-738
-745
-725
-833
-598
-605
-261
-316
-417
-523
-714
-1,423
-1,796
-1,953
-1,531
-799
-606
-552
-473
-473-552-606-799-1,531-1,953-1,796-1,423-714-523-417-316-261-605-598-833-725-745-738-754-799-854-908-1,021-963-551-403-212-7-1949-11-312-3310112627270000
   Capital Surplus 
0
0
0
0
0
0
1,538
182,046
186,186
325,934
326,602
332,404
336,768
341,114
408,866
411,766
413,518
415,603
418,022
420,811
439,048
512,173
518,275
521,285
522,503
523,923
528,458
531,056
560,704
712,713
720,288
930,211
937,134
946,098
954,854
960,180
964,965
970,349
975,653
980,156
0
990,214
994,929
0
0
00994,929990,2140980,156975,653970,349964,965960,180954,854946,098937,134930,211720,288712,713560,704531,056528,458523,923522,503521,285518,275512,173439,048420,811418,022415,603413,518411,766408,866341,114336,768332,404326,602325,934186,186182,0461,538000000
   Treasury Stock000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
632
63,082
1,538
14,807
186,186
325,934
326,602
332,404
336,768
341,114
408,866
411,766
413,518
415,603
418,022
420,811
439,048
512,173
518,275
521,285
522,503
523,923
528,458
531,056
560,704
712,713
720,288
930,211
937,134
946,098
954,854
960,180
964,965
970,349
975,653
980,156
985,651
990,214
994,929
999,319
1,003,709
1,003,709999,319994,929990,214985,651980,156975,653970,349964,965960,180954,854946,098937,134930,211720,288712,713560,704531,056528,458523,923522,503521,285518,275512,173439,048420,811418,022415,603413,518411,766408,866341,114336,768332,404326,602325,934186,18614,8071,53863,0826320000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue3,600
Cost of Revenue-5,644
Gross Profit-2,044-2,044
 
Operating Income (+$)
Gross Profit-2,044
Operating Expense-121,747
Operating Income-123,791-123,791
 
Operating Expense (+$)
Research Development77,476
Selling General Administrative49,915
Selling And Marketing Expenses5,644
Operating Expense121,747133,035
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-123,791
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-118,243-129,339
EBIT - interestExpense = -123,791
-118,243
-117,165
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-123,791-118,243
Earnings Before Interest and Taxes (EBITDA)-118,147
 
After tax Income (+$)
Income Before Tax-118,243
Tax Provision--1,078
Net Income From Continuing Ops-117,165-117,165
Net Income-117,165
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses127,391
Total Other Income/Expenses Net5,5480
 

Technical Analysis of Adverum
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Adverum. The general trend of Adverum is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Adverum's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Adverum Biotechnologies Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 20.90 < 29.70.

The bearish price targets are: 11.50 > 10.40 > 9.7.

Tweet this
Adverum Biotechnologies Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Adverum Biotechnologies Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Adverum Biotechnologies Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Adverum Biotechnologies Inc. The current macd is -1.42587875.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Adverum price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Adverum. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Adverum price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Adverum Biotechnologies Inc Daily Moving Average Convergence/Divergence (MACD) ChartAdverum Biotechnologies Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Adverum Biotechnologies Inc. The current adx is 22.47.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Adverum shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Adverum Biotechnologies Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Adverum Biotechnologies Inc. The current sar is 12.74.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Adverum Biotechnologies Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Adverum Biotechnologies Inc. The current rsi is 28.50. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Adverum Biotechnologies Inc Daily Relative Strength Index (RSI) ChartAdverum Biotechnologies Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Adverum Biotechnologies Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Adverum price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Adverum Biotechnologies Inc Daily Stochastic Oscillator ChartAdverum Biotechnologies Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Adverum Biotechnologies Inc. The current cci is -108.70323615.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Adverum Biotechnologies Inc Daily Commodity Channel Index (CCI) ChartAdverum Biotechnologies Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Adverum Biotechnologies Inc. The current cmo is -62.91927099.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Adverum Biotechnologies Inc Daily Chande Momentum Oscillator (CMO) ChartAdverum Biotechnologies Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Adverum Biotechnologies Inc. The current willr is -95.77836412.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Adverum Biotechnologies Inc Daily Williams %R ChartAdverum Biotechnologies Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Adverum Biotechnologies Inc. The current atr is 1.27254137.

Adverum Biotechnologies Inc Daily Average True Range (ATR) ChartAdverum Biotechnologies Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Adverum Biotechnologies Inc. The current obv is 37,393.

Adverum Biotechnologies Inc Daily On-Balance Volume (OBV) ChartAdverum Biotechnologies Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Adverum Biotechnologies Inc. The current mfi is 10.42.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Adverum Biotechnologies Inc Daily Money Flow Index (MFI) ChartAdverum Biotechnologies Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Adverum Biotechnologies Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-04WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-30RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-21ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Adverum Biotechnologies Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Adverum Biotechnologies Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5028.505
Ma 20Greater thanMa 5013.817
Ma 50Greater thanMa 10017.323
Ma 100Greater thanMa 20012.989
OpenGreater thanClose11.720
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Adverum with someone you think should read this too:
  • Are you bullish or bearish on Adverum? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Adverum? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Adverum Biotechnologies Inc

I send you an email if I find something interesting about Adverum Biotechnologies Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Adverum Biotechnologies Inc.

Receive notifications about Adverum Biotechnologies Inc in your mailbox!